Erlotinib Teva 150 mg filmom obložene tablete
| Name | Erlotinib Teva 150 mg filmom obložene tablete |
|---|---|
| Marketing Authorisation Number | HR-H-787566877 |
| Active Substance | erlotinibum |
| Pharmaceutical Form | filmom obložena tableta |
| Strength | 150 mg |
| Packaging [MA Number for Packaging] | 30 tableta u blisteru, u kutiji [HR-H-787566877-01] 30 tableta u perforiranom blisteru, u kutiji [HR-H-787566877-02] |
| Manufacturer | Teva Gyogyszergyar Zrt., Debrecen, Mađarska
Teva Operations Poland Sp. z o.o., Krakow, Poljska Merckle GmbH, Blaubeuren, Baden-Wuerttemberg, Njemačka Pliva Hrvatska d.o.o., Zagreb, Hrvatska Teva UK Ltd., Eastbourne, East Sussex, Ujedinjeno Kraljevstvo |
| Marketing Authorisation Holder | Teva B.V., Swensweg 5, Haarlem, Nizozemska |
| Marketing Authorisation Date | 13.01.2017 |
| MA Period of Validity | 13.01.2022 |
| MA Revocation Date | 18.02.2021* |
| Classification Number | UP/I-530-09/15-01/200 |
| Registration Number | 381-12-01/30-17-07 |
| Composition | jedna filmom obložena tableta sadrži 150 mg erlotiniba (u obliku erlotinibklorida) |
| Prescription | na recept |
| Type of prescription | ograničeni recept |
| Distribution | u ljekarni |
| Advertising to general public | zabranjeno |
| ATC Code | L01XE03 |
| Medicinal product marketed in the Croatia | Trajni prekid opskrbe |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
| Educational materials for healthcare professionals |
Brošura za zdravstvene radnike, verzija 2 |
*Note
Marketing authorisation has been revoked by request of the marketing authorisation holder. In accordance with Article 113 of Medicinal Products Act (Official Gazette No. 76/13), only a medicinal product in respect of which a marketing authorisation has been granted by the Agency for Medicinal Products and Medical Devices or the European Commision, and a medicinal product in respect of which an authorisation for parallel import or parallel distribution has been granted may be placed on the market of the Republic of Croatia. By way of derogation from this provision, a batch of medicinal product may be on the market for no longer than 18 months following the expiry of revocation of the marketing authorisation, unless its shelf life expires first.
